Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 14/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18612221 | 1.00 | APP (0.55) | APPEPHX2KDM4EMAPTALDH1A1 | |
| SCHEMBL20133425 | 1.00 | APP (0.55) | APPEPHX2KDM4EMAPTALDH1A1 | |
| SCHEMBL20372774 | 0.94 | APP (0.49) | APPEPHX2RARB | |
| SCHEMBL20046548 | 0.93 | APP (0.47) | APPEPHX2 | |
| SCHEMBL20133429 | 0.92 | APP (0.46) | APPEPHX2 | |
| SCHEMBL20234304 | 0.92 | APP (0.46) | APPEPHX2 | |
| SCHEMBL18592227 | 0.87 | EPHX2 (0.43) | APPEPHX2KDM4EMAPTALDH1A1 | |
| SCHEMBL18592228 | 0.87 | EPHX2 (0.43) | APPEPHX2KDM4EMAPTALDH1A1 | |
| SCHEMBL18592230 | 0.87 | EPHX2 (0.43) | APPEPHX2KDM4EMAPTALDH1A1 | |
| SCHEMBL20234303 | 0.86 | KDM4E (0.43) | APPEPHX2KDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-11028088-B2 | Modulators of BTK proteolysis and methods of use | YALE UNIVERSITY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20190276459-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | YALE UNIVERSITY | 2019-09-12 | — | — | US | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | APP 87/4885EPHX2 2978/4885KDM4E 1212/4885 |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | APP 1451/4885EPHX2 2318/4885KDM4E 1254/4885 |
| US-11028088-B2 | Modulators of BTK proteolysis and methods of use | BTK, CBL, CRBN | APP 1477/4885EPHX2 1957/4885KDM4E 1466/4885 |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | APP 432/4885EPHX2 924/4885KDM4E 1438/4885 |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | APP 1314/4885EPHX2 2599/4885KDM4E 1613/4885 |
| US-20190276459-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | APP 1477/4885EPHX2 1957/4885KDM4E 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.